文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌的三线治疗与177Lu-PSMA放射配体治疗:一项系统评价

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-12-16

该系统评价比较了177Lu-PSMA放射配体治疗与三线治疗在转移性去势抵抗性前列腺癌中的疗效与不良反应,纳入12项研究669例接受177Lu-PSMA治疗的患者和16项研究1338例接受三线治疗的患者,结果显示177Lu-PSMA治疗的前列腺特异性抗原(PSA)下降≥50%的比例更高、客观缓解更多、因不良反应停药更少,但中位生存差异无统计学意义。

要点

  • 177Lu-PSMA放射配体治疗PSA下降≥50%的比例高于三线治疗(平均44%对22%,p=0.0002)。
  • 177Lu-PSMA治疗客观缓解率高于三线治疗(109例中31例对275例中43例,p=0.004)。
  • 因不良反应停药在177Lu-PSMA治疗中少于三线治疗(469例中0例对66例中22例,p<0.001)。

核心结论

  • 对于转移性去势抵抗性前列腺癌患者,177Lu-PSMA-617放射配体治疗和177Lu-PSMA显像与治疗(I&T)的疗效优于三线治疗,且不良反应更少。

研究设计与样本

  • 系统评价遵循PRISMA指南,检索Pubmed和Embase截至2017年9月的文献,并在ClinicalTrials.gov检索在研研究,Meta分析采用随机效应模型(PROSPERO ID CRD42017067743)。
  • 12项研究共669例患者报告了177Lu-PSMA放射配体治疗。
  • 16项研究共1338例患者报告了三线治疗。

主要发现

  • 接受177Lu-PSMA放射配体治疗的患者中,43%的患者PSA最大下降≥50%。
  • 接受三线治疗的患者中,21%的患者PSA最佳下降≥50%。
  • 177Lu-PSMA放射配体治疗PSA最佳下降≥50%的比例高于三线治疗(平均44%对22%,p=0.0002,t检验)。
  • 177Lu-PSMA放射配体治疗客观缓解率高于三线治疗(109例中31例对275例中43例,p=0.004,χ2检验)。
  • 177Lu-PSMA放射配体治疗后的中位生存长于三线治疗,但差异无统计学意义(平均14个月对12个月,p=0.32,t检验)。

关键数值与推荐

  • 177Lu-PSMA-617和177Lu-PSMA I&T治疗的不良反应主要为暂时性。
  • 恩扎卢胺(enzalutamide)和卡巴他赛(cabazitaxel)三线治疗后,10%至23%的患者因不良反应中止治疗。
  • 因不良反应中止治疗在三线治疗中多于177Lu-PSMA放射配体治疗(66例中22例对469例中0例,p<0.001,χ2检验)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: There is a controversy as to the relative efficacy of 177Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether 177Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743). METHODS: The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in Pubmed and Embase selected articles up to September 2017. A search in ClinicalTrials.gov indicated ongoing studies. The meta-analysis used the random-effects model. RESULTS: Twelve studies including 669 patients reported 177Lu-PSMA RLT. Overall, 43% of the patients had a maximum decline of PSA of ≥50% following treatment with 177Lu-PSMA RLT. The treatment with 177Lu-PSMA-617 and 177Lu-PSMA for imaging and therapy (I&T) had mainly transient adverse effects. Sixteen studies including 1338 patients reported third-line treatment. Overall, 21% of the patients had a best decline of PSA of ≥50% following third-line treatment. After third-line treatment with enzalutamide and cabazitaxel, adverse effects caused discontinuation of treatment for 10% to 23% of the patients. 177Lu-PSMA RLT gave a best PSA decline ≥50% more often than third-line treatment (mean 44% versus 22%, p = 0.0002, t test). 177Lu-PSMA RLT gave objective remission more often than third-line treatment (overall 31 of 109 patients versus 43 of 275 patients, p = 0.004, χ2 test). Median survival was longer after 177Lu-PSMA RLT than after third-line treatment, but the difference was not statistically significant (mean 14 months versus 12 months, p = 0.32, t test). Adverse effects caused discontinuation of treatment more often for third-line treatment than for 177Lu-PSMA RLT (22 of 66 patients versus 0 of 469 patients, p < 0.001, χ2 test). CONCLUSIONS: As for patients with mCRPC, treatment with 177Lu-PSMA-617 RTL and 177Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. 2017. PMID: 29247284. doi:10.1007/s00259-017-3895-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。